Glutamatergic Modulation in Schizophrenia Treatment

Schizophrenia is increasingly understood as a disorder of glutamatergic signalling, in which hypofunction of the N-methyl-D-aspartate (NMDA) receptor contributes to the emergence of positive symptoms, social withdrawal and profound cognitive impairment. Unlike traditional antipsychotics that primarily target dopamine receptors, glutamatergic modulation seeks to restore excitatory–inhibitory balance through enhancement of NMDA receptor activity or regulation of endogenous co-agonists such as glycine and D-serine. Strategies include direct administration of co-agonists, inhibition of transporters that remove glycine from the synaptic cleft, and blockade of enzymes that degrade D-serine. Preclinical and clinical evidence now supports the potential of these approaches to alleviate negative and cognitive symptoms, which are strongly linked to functional outcome and quality of life. A deeper understanding of underlying molecular pathways offers the prospect of personalised interventions and earlier treatment in high-risk populations.

Research from Nature Portfolio

Foundational work has demonstrated that early supplementation with D-serine during juvenile development can prevent cognitive deficits and attenuate NMDA receptor subunit downregulation in adult offspring following prenatal immune activation. In rodent models, administration of D-serine between postnatal days 28 and 56 normalised hippocampal NMDA receptor expression and preserved performance on memory tasks in animals exposed to maternal inflammation. These findings underscore the potential for early intervention targeting co-agonist pathways to mitigate later emergence of psychosis-like features and suggest avenues for biomarker-driven prevention strategies.

Glutamatergic Modulation in Schizophrenia Treatment publication trend

The graph below shows the total number of articles in glutamatergic modulation in schizophrenia treatment across all publications each year (not limited to Nature Index journals).

Technical terms

N-methyl-D-aspartate (NMDA) receptor: An ionotropic glutamate receptor subtype requiring both glutamate and a co-agonist for activation.

Co-agonist: A molecule (for example glycine or D-serine) that binds alongside the primary neurotransmitter to enable receptor activation.

Glycine transporter 1 (GlyT1) inhibitor: A compound that blocks reuptake of glycine into glial cells, increasing its synaptic availability.

D-amino acid oxidase (DAAO) inhibitor: An agent that prevents enzymatic degradation of D-serine, thereby elevating its concentration at the NMDA receptor.

Mismatch negativity (MMN): An event-related potential reflecting automatic auditory change detection and a proxy for NMDA receptor function.

References

1. Supplementation with D-serine prevents the onset of cognitive deficits in adult offspring after maternal immune activation. Scientific Reports (2016).
2. Neurocognition and NMDAR co-agonists pathways in individuals with treatment resistant first-episode psychosis: a 3-year follow-up longitudinal study. Molecular Psychiatry (2024).
3. The D-amino acid oxidase inhibitor luvadaxistat improves mismatch negativity in patients with schizophrenia in a randomized trial. Neuropsychopharmacology (2023).
4. Development of the novel GlyT1 inhibitor, iclepertin (BI 425809), for the treatment of cognitive impairment associated with schizophrenia. European Archives of Psychiatry and Clinical Neuroscience (2023).